Language:

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

The New England journal of medicine, 2015-05, Vol.372 (20), p.1909-1919 [Peer Reviewed Journal]

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1414325 ;PMID: 25970050

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Author: Mayer, Robert J ; Van Cutsem, Eric ; Falcone, Alfredo ; Yoshino, Takayuki ; Garcia-Carbonero, Rocio ; Mizunuma, Nobuyuki ; Yamazaki, Kentaro ; Shimada, Yasuhiro ; Tabernero, Josep ; Komatsu, Yoshito ; Sobrero, Alberto ; Boucher, Eveline ; Peeters, Marc ; Tran, Ben ; Lenz, Heinz-Josef ; Zaniboni, Alberto ; Hochster, Howard ; Cleary, James M ; Prenen, Hans ; Benedetti, Fabio ; Mizuguchi, Hirokazu ; Makris, Lukas ; Ito, Masanobu ; Ohtsu, Atsushi
Subjects: Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - secondary ; Adult ; Aged ; Aged, 80 and over ; Analysis ; Cancer therapies ; Care and treatment ; Chemotherapy ; Clinical trials ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - pathology ; Dosage and administration ; Double-Blind Method ; Drug Combinations ; Drug therapy ; Evidence-based medicine ; Female ; Humans ; Leukopenia ; Life Sciences ; Male ; Metastases ; Metastasis ; Middle Aged ; Neoplasm Metastasis - drug therapy ; Neutropenia ; Oral medication ; Patients ; Proportional Hazards Models ; Risk factors ; Survival ; Survival Analysis ; Treatment outcome ; Trifluridine - adverse effects ; Trifluridine - therapeutic use ; Uracil - adverse effects ; Uracil - analogs & derivatives ; Uracil - therapeutic use
Is Part Of: The New England journal of medicine, 2015-05, Vol.372 (20), p.1909-1919
Description: TAS-102, a combination of trifluridine and tipiracil in which tipiracil interferes with the deactivation of trifluridine, improved overall and progression-free survival in patients whose disease had progressed after treatment with fluorouracil-containing drug combinations. Fluoropyrimidines have long represented the cornerstone of treatment for colorectal cancer. 1 Such compounds act primarily as inhibitors of thymidylate synthase, the rate-limiting enzyme in the synthesis of pyrimidine nucleotides. 2 Fluorouracil has been combined with folinic acid (also known as leucovorin) to enhance the capacity of fluorouracil to bind to thymidylate synthase. 2 The addition of irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) to fluorouracil and folinic acid, in combination with either a vascular endothelial growth factor inhibitor (bevacizumab) or an epidermal growth factor inhibitor (e.g., cetuximab or panitumumab) if the tumor contains a wild-type RAS gene, represents contemporary standard therapy and has extended . . .
Publisher: United States: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1414325
PMID: 25970050
Source: ProQuest One Psychology
MEDLINE
Alma/SFX Local Collection
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1414325 ;PMID: 25970050

Searching Remote Databases, Please Wait